ProfileGDS5678 / 1416888_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 86% 85% 86% 89% 88% 86% 87% 86% 86% 86% 86% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.5604787
GSM967853U87-EV human glioblastoma xenograft - Control 26.5636286
GSM967854U87-EV human glioblastoma xenograft - Control 36.5530386
GSM967855U87-EV human glioblastoma xenograft - Control 46.5176585
GSM967856U87-EV human glioblastoma xenograft - Control 56.5212686
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.7936489
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5922588
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.553186
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6395687
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5557586
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5448186
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5369286
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5838986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6407687